Intelligence · Clinical Pipeline
Neurology & CNS · Approved programs
Neurology & CNS programs at Approved programs — ClinicalTrials.gov pipeline intelligence.
- Programs
- 64
Quick answer
Neurology & CNS Approved programs programs: NovaPharmaNews indexes 64 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- Teva Pharma 12 programs
- BRIGHT MINDS BIOSCIENCES 5 programs
- Novartis India 5 programs
- Takeda 5 programs
- Chinese Academy of 4 programs
- First People's Hospital 3 programs
- Disc Medicine 2 programs
- Hospital Authority 2 programs
- Jazz Pharmaceuticals Ireland 2 programs
- SUPERNUS PHARMACEUTICALS 2 programs
- Théa Pharma Ireland 2 programs
- Acadia Pharmaceuticals 1 programs
-
AGEE cream
Teva Pharma GmbH
Multiple Sclerosis
1 trial -
APOKYN
SUPERNUS PHARMACEUTICALS, INC.
Parkinson's Disease
2 trials -
Alcohol Wipes vs. No Alcohol Wipes
Teva Pharma GmbH
Multiple Sclerosis
1 trial -
Antiepileptic drug therapy
United Therapeutics Europe Ltd
Epilepsy
1 trial -
Aripiprazole
Otsuka Beijing Research Institute
Schizophrenia
3 trials -
Brand lamotrigine
BRIGHT MINDS BIOSCIENCES INC.
Epilepsy
1 trial -
Butylphthalide
The First People's Hospital of Lianyungang
Focal Epilepsy
1 trial -
CREXONT ER
Amneal Pharma Europe Ltd
Parkinson Disease
2 trials -
Cannabidiol Oral Solution [Epidiolex]
Jazz Pharmaceuticals Ireland Limited
Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
1 trial -
Clozapine
BRIGHT MINDS BIOSCIENCES INC.
Schizophrenia
1 trial -
Copaxone
Teva Pharma GmbH
Multiple Sclerosis
2 trials -
DONEPEZIL, DONEPEZIL
Pari Pharma GmbH
Interest of adding donepezil to the non-medicinal care pathway recommended in France for Alzheimer's disease
1 trial -
Desvenlafaxine Succinate
Grace Therapeutics
Vascular Depression
1 trial -
Dexmedetomidine
BioXcel Therapeutics
Schizophrenia Agitation
1 trial -
Dexmedetomidine Injectable Solution
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Epilepsy
1 trial -
Dimethyl fumarate
Biogen
Multiple Sclerosis
1 trial -
Esketamine
The First People's Hospital of Lianyungang
Postpartum Depression
1 trial -
Folic Acid
Cardiff Oncology
Depression
1 trial -
Glatiramer Acetate
Teva Pharma GmbH
Relapsing Remitting Multiple Sclerosis
5 trials -
Iloperidone
Vanda Pharmaceuticals Netherlands B.V.
Schizophrenia
5 trials -
Kesimpta 20 mg solution for injection in pre-filled syringe
Novartis Pharmaceuticals
Relapsing forms of Multiple Sclerosis (RMS)
1 trial -
Ketamine
Teva Pharma GmbH
Treatment Resistant Depression
1 trial -
Lecanemab 10 mg/kg
The First People's Hospital of Lianyungang
Alzheimer s Disease
1 trial -
Lubiprostone
Takeda
Multiple Sclerosis
1 trial -
MIYAIRI 588
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Depression Mild
1 trial -
Mayzent 0.25 mg film-coated tablets, Mayzent 2 mg film-coated tablets, Mayzent 1 mg film-coated tablets, BAF312, BAF312, BAF312
Verona Pharma Ireland Limited
Active progressive multiple sclerosis course after an initial relapse clinical course
1 trial -
Minocycline
BRIGHT MINDS BIOSCIENCES INC.
Schizophrenia
1 trial -
Ocrevus 300 mg concentrate for solution for infusion
Hoffmann-La Roche
Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS) [in line with the locally approved indications]
1 trial -
Ofatumumab
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
1 trial -
Oral Zonisamide Therapy
Affiliated Hospital of Nantong University
Epilepsies, Partial
1 trial -
PERSERIS
Indivior Pty Ltd
Schizophrenia
1 trial -
Paliperidone ER
Hospital Authority, Hong Kong
Schizophrenia
1 trial -
Pimavanserin
Acadia Pharmaceuticals B.V.
Parkinson Disease Psychosis
1 trial -
RITALINE L.P. 10 mg, gélule à libération prolongée
Tour Hekla
Attention Deficit Disorder with or without Hyperactivity (ADHD) is a neurodevelopmental disorder characterized by disabling symptoms of inattention and/or hyperactivity-impulsivity beginning before the age of 12 with significant personal, social, academic and/or occupational impact (American Psychiatric Association 2013). This disorder, whose prevalence is around 5% in children and adolescents, affects 2.6% of adults (American Psychiatric Association 2013; Song et al. 2021).
1 trial -
RIVASTIGMINE, Rivastigmin adhesive plaster 9.5 mg placebo containing 0 mg of rivastigmin, Rivastigmin adhesive plaster 4.6 mg placebo containing 0 mg of rivastigmin, RIVASTIGMINE
Disc Medicine
Depression
1 trial -
ROP
GlaxoSmithKline
Parkinson Disease
1 trial -
Ramelteon
Takeda
Schizophrenia
1 trial -
Rasagiline
Teva Pharma GmbH
Parkinson's Disease
5 trials -
Rasagiline Mesylate
Teva Pharma GmbH
Parkinson's Disease
8 trials -
Rasagiline/Placebo
Teva Pharma GmbH
Parkinson's Disease
1 trial -
Rivastigmine
Novartis Pharmaceuticals
Alzheimer's Disease
1 trial -
Rivastigmine
Atrium Therapeutics
Parkinson's Disease
1 trial -
Rivastigmine transdermal patch
Novartis Pharmaceuticals
Alzheimer's Disease
1 trial -
SULPIRIDE , QUETIAPINE , PERPHENAZINE , CLOTIAPINE , ZIPRASIDONE , HALOPERIDOL , SERTINDOLE , PALIPERIDONE , ZUCLOPENTHIXOL , CARIPRAZINE , LEVOMEPROMAZINE , LURASIDONE , BREXPIPRAZOLE , AMISULPRIDE , CLOZAPINE , CHLORPROMAZINE , RISPERIDONE , FLUPHENAZINE , PROMAZINE , ARIPIPRAZOLE , ASENAPINE , OLANZAPINE , FLUPENTIXOL
Disc Medicine
schizophrenia, schizoaffective disorder, schizophrenifom disorder
1 trial -
Sativex
Jazz Pharmaceuticals Ireland Limited
Multiple Sclerosis
2 trials -
Selective serotonin reuptake inhibitor (SSRI)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Anxiety Depression
1 trial -
Shared Solutions® plus MS Center v. Shared Solutions®
Teva Pharma GmbH
Multiple Sclerosis
1 trial -
Sodium valproate
Chinese University of Hong Kong
Epilepsy
1 trial
Frequently asked questions
How many neurology & cns Approved programs programs exist?
64 programs match both the therapeutic area and stage filters in our published index.
Data attribution: Data sources · All pipeline programs